Ruti Aga and the Prescription No Clinic Ever Wrote

There was a piece of paper. It carried the letterhead of a clinic, the signature of a doctor, and a dose of methylprednisolone — the drug used in knee-joint injections. When investigators from the Athletics Integrity Unit (AIU) reached that clinic, the reply came back that no such prescription had ever been issued from there. The man whose signature sat on it turned out to be a family member of Ruti Aga, with no medical registration to his name. Under questioning he said he had used an old prescription pad from a former workplace. One document. Three independent verifications. Three failures.

The statement the AIU released on Thursday leads with the number six. The real story sits beneath that number — an athlete who had a legally open route through a medication case, and who closed it herself with a forged sheet of paper. This report is a dig into that sheet of paper.

Context: a 2:18 marathoner and a March morning

Ruti Aga is an Ethiopian marathoner, 32 years old. She belongs to that rare category of athlete who never reaches world-record altitude but sits persistently in the top three of major races. She was second at the 2026 Berlin Marathon, and that entry is still in my notebook because the most striking feature of her splits was how flat they were — as fast in the first 10 kilometres as in the last; only a runner who has already solved the arithmetic of the finish runs like that. She won the 2026 Tokyo Marathon. Three second places at World Marathon Majors. No world championship or Olympic medal.

In March she won a half marathon in China. The in-competition sample taken after that race came back positive. Substance: methylprednisolone. Her explanation was straightforward — a knee injury was being treated, the medication was taken on medical advice. The AIU did not accept the explanation; it asked for the paperwork behind it. That is where the case turned. She had been provisionally suspended since 10 September, and Thursday's decision made that same date the start of the ban. Six years. The next time she is eligible to race, she will be close to 38.

No time from that Chinese half marathon is public. No splits, no field strength, no season's best. Which means any comment on the performance itself would be invention. What is known is that she won — and winning implies a World Athletics Label-tier elite field, which implies testing was present. As a performance story, this case is empty. As a disciplinary story, it is dense.

How six years is assembled

The AIU's figures come in two parts: two years for presence, four years for tampering. The sum is itself a statement.

Two years is the standard sanction where a substance is found in the body but investigators cannot establish that it was taken with intent to enhance performance. Four years is the standard sanction the Code attaches to tampering. The six-year total tells us the panel rejected the relief that is normally available — the no-significant-fault argument that can reduce a presence sanction. In the moment she submitted a forged prescription, she broke the strongest part of her own defence.

Backdating the ban to 10 September is not leniency. Time served under provisional suspension counts against the sanction anyway; the athlete gains nothing real. What is not stated matters as much — what happens to the March result and its prize money, and where the world ranking points accrued after that date go. Standard procedure voids the result of the competition at which the sample was collected. The statement is silent on it.

The substance the newspapers mislabelled

A technical correction is necessary here, because without it the entire case gets read in the wrong direction. Several reports described methylprednisolone as a "prohibited steroid." That is imprecise. It is not an anabolic steroid; it is a glucocorticoid, class S9 on the WADA Prohibited List. And the List's condition is the crucial part: S9 substances are prohibited in-competition only, by injection, oral or rectal route. A knee injection given out of competition is entirely legal.

Which means the case never hinged on whether a steroid was taken. It hinged on route and timing relative to the competition. A road race's testing window opens at 23:59 the day before the race. An injection given days earlier, with residue still present, becomes a violation automatically — regardless of therapeutic intent.

That is where this case loses its way. Aga had a legitimate defence path available: real medical records, the date of the injection, the route, the clinical necessity — enough to bring the presence charge into the no-fault or minor-fault range, where the sanction can shrink to a reprimand. The route was not closed by an investigator. It was closed inside the athlete's own camp. In my reading, the case began with a medication and ended with a prescription.

The knee: injury is a site, not a verdict

I have spent two decades digging through these layers of athletics, and my biggest lesson since 2026 has been this — solitude taught me that injury is a site, not a verdict. Chronic knee pathology in high-mileage marathoners is not an exception; it is the sport's most common failure point. And a glucocorticoid injection into the joint is its most standard treatment.

Which is why the explanation is technically credible — and why it proved legally fatal. If the treatment was real, the paperwork would have been real. Why would an athlete with genuine records take the risk of substituting a forged one? The AIU did not have to ask that question. It rises on its own from that sheet of paper.

Where the camp's real weakness shows

The most bruising detail here is not the drug but the absence of a medical system. The "doctor" was a family member with no registration, who invoked an old prescription pad, in the name of a clinic that flatly denied issuing anything. An athlete with a credentialed team physician never manufactures a document like that.

A second gap sits beside it: Therapeutic Use Exemption infrastructure. A properly managed athlete either holds a TUE or observes the route-specific washout period set for that drug and that route. Neither appears to have happened. My inference is that the moment the forged prescription was chosen, it was already settled that the camp had no doctor, no protocol, and nobody who could say how many days must separate an injection from a race.

Where the four years came from

The four-year tampering sanction did not come from the document alone. It also came from statements made during interview. In an AIU investigation the interview is evidence alongside the paperwork — and in interviews with Ethiopian road runners, language and translation conditions have been a recurring point of contention. That does not weaken the case; it explains where it began. My reading is that this investigation travelled past a routine in-competition test and into document verification, and that once it arrived there, the athlete stood alone.

The China circuit: where the fee economy and the testing economy meet

This case also has a geography. In the gaps between Majors, Asia's label races are a separate income tier for East African marathoners — relatively low risk, a decent appearance fee, a small race count. For a 2:18–2:20 runner that is a rational economic model. It is also now the AIU's highest-yield testing zone. The appearance-fee economy and the testing economy are colliding in the same races.

That collision has a human side. A marathoner racing on an aching knee is not only fighting her own body; she is fighting the contract that calls her there for a fee. A glucocorticoid is the cheapest, most available tool for hiding that pain. In a camp with no medical governance, the line between treatment and violation can vanish on a single morning.

The most counter-intuitive layer

Here is the turn few people stop at. Six years was imposed for a substance with no proven performance benefit in endurance sport. A glucocorticoid reduces pain and inflammation; it does not build muscle. In anabolic steroid cases, where the performance gain is clear, sanctions often sit at or below this level.

Two things follow, and they must be held together. First — the length of this ban came from paperwork, not pharmacology. The four added years were for document tampering, not for the substance. The lesson is that an athlete today should fear her own explanation more than the injection. Second — reading this as "another cheat caught" is easy, and it puts the finger in the wrong place. The enforcement frontier has moved from the sample to the paper trail, and the athletes most exposed to it are precisely those whose camps have the thinnest medical infrastructure.

My old line returns here: the break did not happen at the baton; it happened in the silence between the injection and the race. Had a credentialed doctor stood inside that gap, this article would not need to exist.

The record, now split in two

Aga's name carries the 2026 Tokyo title and three Major second places. The violation is anchored to a March race in a later year. Absent proof of earlier use, earlier results are not automatically annulled. Her historical record survives, then — with a ban attached that will depress the value of every contract that might have followed. Sponsorship in distance running is already thin; a name tied to document forgery is the easiest thing to remove from a thin space.

What to watch

As a performance matter, this barely moves Ethiopia's marathon arithmetic. In a country with a queue of 2:14–2:16 runners, the removal of a 32-year-old 2:18 athlete leaves no hole in national selection. What moves is the medical governance question.

Three things bear watching. One — the CAS appeal window, typically about 21 days from a reasoned decision; document-based findings are hard to overturn, so appeal risk is low. Two — the scope of disqualification: the March result, its prize money and subsequent ranking points are all unstated. Three — was the agent or management investigated? The AIU named only the family member. Who suggested or accepted that document remains unanswered.

My expectation is that more cases from the same training cluster are in the pipeline, because the same informal medical networks serve many athletes. If that is right, the next story should not be about one runner but about an entire camp.

A prospect is never one highlight; it is a stratigraphy of small choices. Knee pain was the bottom layer of that stratigraphy. A signature on an old prescription pad was the layer above it. Six years is the top layer, where the outcome gets recorded. The question is who a marathoner's camp calls the next time a knee swells — a registered doctor, or the relative who still has an old pad in a drawer.